PubMed Health⌕ Search

Biomedical subjects

G M Simpson

Publications and source records attributed to G M Simpson.

At least 37 records · Page 2Linked to original sources
PubMed1977

Deanol in the treatment of tardive dyskinesia.

Ten hospitalized chronic psychotic patients with symptoms of tardive dyskinesia were given deanol and placebo, each for 8 weeks following a double-bline, crossover design. No psychotropic agents were administered during the trial. Improvement occurred in all patients during the first treatment phase regardless of which drug the patients received; seven patients were on deanol and three on placebo during this time. The possible reasons for this decrease were discussed. It was concluded that deanol may have contributed to the decline but that its effect on the disorder was not dramatic.

Aged↗
PubMed1977

Efficacy of loxapine in the treatment of paranoid schizophrenia.

A combined analysis of data from 11 controlled studies of loxapine versus either chlorpromazine or trifluoperazine in acute schizophrenia (5 studies) and chronic schizophrenia (6 studies) showed statistically significant superiority of loxapine on several items and factors of standardized psychiatric rating scales. Upon review of these findings, it was observed that the rating scale symptoms for which loxapine appeared superior to the reference compounds could, in the main, be considered a broad paranoid "cluster". The data were then reanalyzed to detect possible differences in efficacy of loxapine versus the reference compounds in those patients with a clinical diagnosis of schizophrenia, paranoid type and in those patients of any diagnostic subtype other than paranoid. Results of these analyses demonstrated clear superiority of loxapine in paranoid schizophrenic patients; nonparanoid patients responded at least equally as well to loxapine as to the reference compounds. Findings could not be attributed to inadequate dosages of the references compounds or inequality of treatment groups at baseline.

Adult↗
PubMed1976

Two dosages of imipramine in hospitalized endogenous and neurotic depressives.

Fifty-one newly hospitalized depressed patients participated in a double-blind comparison of two dosage levels of imipramine hydrochloride (150 mg vs 300 mg daily). Although some patients were suffering from neurotic depressions, they, together with the endogenous depressives, were a severely depressed group who required hospitalization. Improvement occurred with both dosage regimens, although a greater and more consistent improvement was noted in the 300-mg group than in the 150-mg group. There were a few differences between the response of the endogenous and that of the neurotic depressives, as assessed by the physician and self=rating scales. However, endogenous depressives who received 150 mg were overrepresented in the treatment failure group. A comparison of the response of deluded and nondeluded depressives indicated that the deluded patients responded less well than the nondeluded depressives, although half of the delusional group did respond to the treatment.

Adjustment Disorders↗
PubMed1976

A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients.

A study was conducted evaluating the efficacy of loxapine succinate in newly admitted schizophrenic patients through a four-week double-blind comparison with trifluoperazine. Twenty-four patients received between 40 and 80 mg loxapine succinate daily and 19 patients received between 20 and 50 mg trifluoperazine daily. The two groups showed comparable significant improvement on the BPRS and CGI. The discharge and termination rates of the two groups were not significantly different and the incidence and severity of side effects, most frequently extrapyramidal signs, were similar in both groups. Loxapine succinate was judged to be an effective treatment for newly admitted schizophrenic patients.

Adolescent↗
PubMed1976

Lithium in tardive dyskinesia.

A single blind trial and a placebo controlled double blind trial of lithium were carried out in elderly patients with tardive dyskinesia. In the pilot study, neuroleptics were continued: in the controlled trial, neuroleptics were discontinued. The results of both studies were essentially negative. Thus, the suppression effect of neuroleptics is much more dramatic than anything seen in the two studies. Several reasons for this were discussed namely, the severity and chronicity of the symptoms.

Aged↗
PubMed1976

The 24-hour lithium level as a prognosticator of dosage requirements: a 2-year follow-up study.

The authors have previously described a technique whereby individual lithium dosage requirements can be predicted from 24-hour blood samples. Further experience over a 2-year period has shown the predictions to be reproducible over time. A micromethod for lithium determination is described, as are several cases in which aberrant results were found to indicate inadequate laboratory techniques or patients' failure to take medication. Because the technique reveals immediately those patients at the extremes of dosage ranges, toxicity and the need for frequent sampling can be avoided.

Bipolar Disorder↗
PubMed1976

Extrapyramidal side effects in lithium maintenance therapy.

The authors neurologically examined 36 patients who had been maintained on lithium therapy for periods ranging from 6 months to 7 years to determine the presence of parkinson-like side effects. Only a few patients demonstrated rigidity, including cogweel rigidity, and this was at a low level of severity. These results do not support the previously reported frequent occurrence of cogwheel rigidity in patients on lithium maintenance.

Basal Ganglia Diseases↗
PubMed1976

A two year trial of loxapine succinate in chronic psychotic patients.

Thirty-one chronic psychotic patients were treated with loxapine succinate, 20 for two years and eleven for one year, in order to evaluate its long-term efficacy and safety. Results presented here indicate that loxapine succinate is an effective treatment for chronic schizophrenia over a period of at least two years. Improvement, which occurred during the first six months of treatment (mostly during the first month), was maintained over the following year and a half. Unwanted effects were most frequent inthe early months of treatment and decreased as the two year trial progressed. No specifically long-term side effects were observed. The most frequent side effects were mild to moderate extrapyramidal signs. Blood pressure decreased and pulse rate increased, while remaining within normal limits, and returned to normal or near normal levels during the second year of treatment. Weight increased steadily during the two years and dropped markedly during the four week post-drug period. No drug-related abnormal laboratory findings were observed. It may be concluded that loxapine succinate is a safe and effective maintenance treatment for chronic schizophrenia.

Adult↗
PubMed1976

Psychotic exacerbations produced by neuroleptics.

Thirteen schizophrenic patients who developed abnormal psychotic behavior as an adverse reaction to a neuroleptic are described. A. Three patients showed a marked increase in the psychopathology during neuroleptic treatment. These episodes were treated by decreasing or discontinuing the neuroleptics. They did not respond to anticholinergic durgs nor did they respond to an increase in dosage, (another side effect previously reported and referred to here) indeed this treatment worsened the situation. B. Ten patients showed a mixed picture of catatonic excitement or inhibition on neuroleptics and several developed hallucinatory episodes. All of these exacerbations were terminated by anticholinergic injections. Other more familiar CNS abnormalities produced by neuroleptics are briefly discussed.

Acute Disease↗